Orexin receptor 2 (OX2R) agonist

Search documents
Centessa Pharmaceuticals (CNTA) Earnings Call Presentation
2025-06-26 12:41
Pipeline and Milestones - Centessa Pharmaceuticals 专注于发现和开发针对患者的变革性药物[7, 50]。 - 公司预计在 2025 年实现 OX2R 激动剂管线的多个临床里程碑[7, 50]。 - ORX750 的 2a 期临床数据预计在 2025 年公布,针对嗜睡症 I 型 (NT1)、嗜睡症 II 型 (NT2) 和特发性嗜睡症 (IH) 患者[10]。 - ORX142 在急性睡眠剥夺的健康志愿者中的临床数据预计在 2025 年公布[10]。 - ORX489 正在推进 IND (新药研究申请) 支持性研究[10, 49]。 ORX750 and Market Opportunity - ORX750 是一种高效、选择性的 OX2R 激动剂,有潜力重新定义睡眠-觉醒障碍患者的标准治疗方法[21]。 - NT1、NT2 和 IH 代表着庞大的潜在患者群体,美国约有 62 万名患者[23, 25]。 - 在美国,大约有 27 万名 NT1、NT2 和 IH 患者被诊断和治疗[23, 25]。 ORX750 Clinical Data - 在一项研究中,2.5 毫克、3.5 毫克和 5.0 毫克剂量的 ORX750 在急性睡眠剥夺的健康志愿者中均产生了超过 30 分钟的 MWT LS 平均睡眠潜伏期[29]。 - ORX750 在 KSS 评分中显示出剂量依赖性的显著改善,与安慰剂相比,剂量 ≥ 2.5 毫克时具有显著性[32]。 - ORX750 显示出良好的安全性和耐受性[38]。
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
Newsfilter· 2025-03-06 21:14
Group 1 - Centessa Pharmaceuticals announced the presentation of Phase 1 clinical trial data for ORX750, a novel OX2R agonist aimed at treating narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) at the AAN 2025 Annual Meeting [1] - The ongoing Phase 2a clinical trial (CRYSTAL-1) is evaluating ORX750 in participants with NT1, NT2, and IH [1] - The poster presentation will take place on April 5, 2025, with details including the title, abstract number, and presenter provided [2] Group 2 - Centessa Pharmaceuticals is focused on developing best-in-class OX2R agonists for sleep-wake disorders and anticipates potential applications in treating cognitive deficits and excessive daytime sleepiness [3] - The company is also advancing an earlier stage pipeline in immuno-oncology utilizing its proprietary LockBody® technology platform [3]